Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
- Detailed Technology Description
- None
- *Abstract
-
The present invention provides a method of protecting normal cells of the oral cavity, oropharynx, esophagus, stomach, small intestine and colon against the damaging effects of an anticancer agent or ionizing radiation by providing genes encoding antioxidant proteins protective to normal somatic cells, specifically MnSOD. Additional embodiments provide a method of delivering the protective protein via ingestion or inhalation. Applications:1) Cytoprotective agent for cancer patientsAdvantages:1) Allows proper dose escalation of radiation therapy and chemotherapy2) Can be localized to specific organs3) Does not cause increase in blood pressure, kidney failure, nausea, vomiting, and transient hypotension attributable to other cytoprotective agents4) First targeted radioprotective agent that demonstrates efficacy in lung and esophagus cancer5) Competing technologies have questionable efficacy in preventing damage to normal tissuesStage of Development:Currently in Phase I/II clinical studies at the University of PittsburghCombined with cases 47 and 237
- *Principal Investigator
-
Name: Michael Epperly, Associate Professor
Department: Med-Radiation Oncology
Name: Joel Greenberger, Professor & Chairman
Department: Med-Radiation Oncology
Name: Michael Zigmond, Professor of Neurology
Department: Med-Neurology
- Country/Region
- USA
For more information, please click Here
